Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Antimicrob Agents Chemother. 2010 Feb;54(2):773-7. doi: 10.1128/AAC.00348-09. Epub 2009 Nov 23.
With the current high prevalence of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) strains but in light of the general belief that beta-lactam antibiotics are more effective than vancomycin against infections caused by methicillin-susceptible S. aureus (MSSA) isolates, clinicians may utilize antistaphylococcal penicillins in combination with vancomycin for the empirical treatment of S. aureus infections. Vancomycin is considered to kill MSSA more slowly than oxacillin. Thus, we sought to evaluate the interaction of the combination of oxacillin and vancomycin on bacterial killing in vitro. Ten clinical isolates of MSSA isolated in the year 2000 were investigated. The killing observed at 24 h by vancomycin at 20 microg/ml, oxacillin at 16 microg/ml, or the combination did not differ (approximately 2.5 to 3.5 log10 CFU/ml). In a separate experiment, we assessed bacterial killing in a dynamic model simulating the free plasma concentration profiles expected following the administration of a combination of vancomycin at 1 g every 12 h and oxacillin at 1 g every 6 h. The time-kill profiles of these regimens against S. aureus ATCC 29213 were comparable to those observed in the fixed-concentration experiments. Using these methods, we found no evidence that vancomycin antagonized the bactericidal effect of oxacillin or that there was any benefit from use of the combination.
由于耐甲氧西林金黄色葡萄球菌 (MRSA) 菌株的感染率目前很高,但鉴于一般认为β-内酰胺类抗生素对甲氧西林敏感金黄色葡萄球菌 (MSSA) 分离株引起的感染比万古霉素更有效,临床医生可能会使用抗葡萄球菌青霉素与万古霉素联合用于金黄色葡萄球菌感染的经验性治疗。万古霉素被认为比苯唑西林杀死 MSSA 更慢。因此,我们试图评估苯唑西林和万古霉素联合使用对体外细菌杀伤的相互作用。研究了 2000 年分离的 10 株临床 MSSA 分离株。在 24 小时时观察到的 20 μg/ml 万古霉素、16 μg/ml 苯唑西林或联合用药的杀菌作用没有差异(约 2.5 至 3.5 log10 CFU/ml)。在另一个实验中,我们在模拟万古霉素 1 g 每 12 小时和苯唑西林 1 g 每 6 小时给药后预期的游离血浆浓度曲线的动态模型中评估了细菌的杀菌作用。这些方案对金黄色葡萄球菌 ATCC 29213 的时间杀菌曲线与固定浓度实验中观察到的曲线相似。使用这些方法,我们没有发现万古霉素拮抗苯唑西林杀菌作用的证据,也没有从联合用药中获益的证据。